NCT07022171 Mechanisms of Transcutaneous Auricular Vagus Nerve Stimulation in Depression
| NCT ID | NCT07022171 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Max-Planck-Institute of Psychiatry |
| Condition | Depressive Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 86 participants |
| Start Date | 2025-03-18 |
| Primary Completion | 2030-03-17 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Invasive vagus nerve stimulation (VNS) is an approved treatment of treatment-resistant depression (TRD) in Europe and in USA. Because of the associated possible surgical complications as well as side effects, invasive VNS is applied limitedly in the treatment of depression. Transcutaneous auricular VNS (tVNS), on the other hand, is a non-invasive alternative to traditional invasive VNS. tVNS is still considered an experimental treatment for depression. This is due to the limited high-quality evidence from randomized clinical studies, the not yet fully understood biological mechanisms of action, along with overall limited knowledge about the optimal stimulation parameters. To address these issues, the AddVNS study was initiated. The AddVNS study intends to recruit n=86 patients of the Max Planck Institute of Psychiatry with depression. The patients participating in the AddVNS study are going to receive either tVNS or sham tVNS for a period of 6 weeks. The primary objective of the study is to identify biological, psychological, socio-economic, and clinical biomarkers associated with treatment progression and response to treatment in patients with depression undergoing tVNS. To achieve this, an exploratory design with an assessment of many different parameters including psychophysiology, imaging, blood-based multi-omics, microbiome, psychometrics and neuropsychology will be used.
Eligibility Criteria
Inclusion Criteria: 1. age 18-65 years, legally competent and able to provide informed consent; 2. diagnosis of a depressive episode (MDD or bipolar disorder) according to DSM 4/DSM 5 or ICD-10/ICD-11; 3. signed informed consent documents for the AddVNS study; 4. signed informed consent and participation in the biobanking project of MPIP; 5. use of a safe contraceptive method Exclusion Criteria: 1. age \< 18 years or age \> 65 years; 2. pregnancy or planning to get pregnant during the study period, breastfeeding; 3. legal supervision; 4. pervasive developmental disorders and/or intellectual disability; 5. acute substance abuse (e.g., alcohol, prescription or illicit drugs); 6. severe neurological disease; 7. technically or anatomically not possible tVNS (e.g., microtia or anotia, vagotomy); 8. current treatment with an established neurostimulation method (e.g., ECT, rTMS, VNS); 9. metallic foreign bodies, implanted intracranial devices or cerebral shunts; 10. severe general illness (e.